Contribution of the Local RAS to Hematopoietic Function: A Novel Therapeutic Target.

Item

http://www.wikidata.org/entity/Q38156167

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Contribution of the Local RAS to Hematopoietic Function: A Novel Therapeutic Target.

@en

type

Item

label

Contribution of the Local RAS to Hematopoietic Function: A Novel Therapeutic Target.

@en

prefLabel

Contribution of the Local RAS to Hematopoietic Function: A Novel Therapeutic Target.

@en

P1476

Contribution of the Local RAS to Hematopoietic Function: A Novel Therapeutic Target.

@en

P2093

Gere S Dizerega

http://www.w3.org/2001/XMLSchema#string

Kathleen E Rodgers

http://www.w3.org/2001/XMLSchema#string

P2860

Enalapril-associated anemia in renal transplant recipients treated for hypertension

Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells

Adult renal mesenchymal stem cell-like cells contribute to juxtaglomerular cell recruitment.

Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients.

Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells.

Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer.

Accelerated hematopoietic recovery with angiotensin-(1-7) after total body radiation.

Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy.

Mesenchymal stem cells differentiate into renin-producing juxtaglomerular (JG)-like cells under the control of liver X receptor-alpha

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

P304

157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FENDO.2013.00157

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258117799

http://www.w3.org/2001/XMLSchema#string

P698

24167502

http://www.w3.org/2001/XMLSchema#string

P932

3805949

http://www.w3.org/2001/XMLSchema#string